Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WuXi PharmaTech, a medical device R&D outsourcing company, has signed a new three-year collaboration agreement with AstraZeneca.
Subscribe to our email newsletter
Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca’s designs, which will further expand AstraZeneca’s global compound collection.
In April 2006, WuXi PharmaTech and AstraZeneca entered into a two-year $14 million collaboration agreement that WuXi PharmaTech successfully delivered more than 100,000 compounds two months ahead of schedule.
Ge Li, chairman and CEO of WuXi PharmaTech, said: “This new collaboration agreement further strengthens our already productive relationship with AstraZeneca, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction.”